Who’s really at risk for fractures, and how should we be treating them?
Most fragility fractures occur in patients without osteoporosis. Should we rethink who gets treated? And could just one or two IV infusions (spread years apart) of zoledronate prevent fractures for years? Have the concerns about bisphosphonates been overblown?
Find out all the nuances on this episode of Beyond Journal Club, a series brought to you by Core IM in collaboration with NEJM Group.
🔹 Sponsor: Oakstone CME
Use the code "CORE25" for 25% off: https://www.coreimpodcast.com/MKSAP
Timestamps:
(00:59) | Diagnosing Osteoporosis and Hidden Fracture Risk
(05:38) | Evolution of Bisphosphonate Use in Osteoporosis Treatment
(07:51) | Current Use of Bisphosphonates: Benefits, Risks, and Side Effects
(10:31) | Exploring Non-Bisphosphonate Options for Fracture Prevention
(11:44) | Teriparatide and Alternative Osteoporosis Medications
(14:53) | Inside the Latest Bisphosphonate Clinical Trial
(18:07) | Key Findings from the Zoledronate Fracture Prevention Study
(22:38) | Public Health Impact of Fracture Prevention Strategies
(24:24) | Final Takeaways and Expert Perspectives on Osteoporosis Care
Tags: CoreIM, Internal Medicine, Primary Care, Medical Education, IMCore, Physician Assistant, Nurse Practitioner, Medical Student, Osteoporosis, Fragility Fractures, Zoledronate, Bone Health